P63.04 Dysbiosis of Sputum and Gut Microbiota Modulate Development and Distant Metastasis of Non-Small Cell Lung Carcinomas

Lung cancer (LC) is the leading cause of cancer-related deaths mortality worldwide, with non-small cell lung (NSCLC) being most common form LC. Despite recent development therapies for NSCLC, tumor metastasis main recurrence and in patients NSCLC. Although dysbiosis gut microbiota have been associated their relative contributions are unclear. In addition, roles distant (DM) still illusive. We enrolled total 121 individuals who completed our study protocol. Among which, 87 were newly diagnosed NSCLC had not previously received any anticancer therapy nor treated antibiotics, while 34 healthy volunteers. classified into distinct disease stages (i.e. from I to IV) according 8th American Joint Committee on Cancer guidelines. Then, we collected 30 sputum 29 fecal samples controls 66 85 patients, submitted them 16S sequencing. To further validate play important C57BL/6 adult female mice (six weeks age) antibiotic cocktail (ABX) vancomycin, neomycin, ampicillin metronidazol drinking water starting 2 before inoculation. Subcutaneous model was established by injecting murine Lewis tagged luciferences (LLC-luc) subcutaneous layer mice's right back. found significant perturbations gut- sputum- DM. obtained better Machine-learning models patient stratification using both than either dataset, highest area under curve (AUC) value 0.842; surprisingly, contributed more gut. Several microbial-biomarkers shared microbiota, indicating similar at body sites. Microbial-biomarkers mostly shared, suggesting biomarkers could be acquired early. Surprisingly, Pseudomonas aeruginosa, a species wound infections, brain metastasis, types DMs different microbial-biomarkers. Furthermore, significantly larger tumors antibiotics-treated mice, confirming that indeed promote growth. Our results indicate addition gut-microbiota, sputum-microbiota contribute improve performance patient-stratification models. Mice experiments suggest favorable clinical outcomes accomplished restoring normal warrant research underlying molecular mechanisms.